ALZHEIMER - The Salt Lake Tribune http://www.sltrib.com/feeds/topics/ALZHEIMER News from The Salt Lake Tribune en-us webmaster@sltrib.com (Webmaster) NFL notes: Broncos owner giving up control due to Alzheimer’s http://www.sltrib.com/sltrib/sports/58217730-77/bowlen-broncos-elway-pat.html.csp <div class="hnews hentry item"> <h4><a class="url entry-title" href="http://www.sltrib.com/sltrib/sports/58217730-77/bowlen-broncos-elway-pat.html.csp">NFL notes: Broncos owner giving up control due to Alzheimer’s</a></h4> <span class="author source-org vcard"><span class="org fn">The Associated Press</span></span> <h5><span class="updated" title="2014-07-24T17:41:25.24-06:00">Updated Jul 24, 2014 05:41PM MDT</span></h5> <div class ="entry-content">Englewood, Colo. • Even as dementia began to rob him of some of his fondest memories over the past few years, Denver Broncos owner Pat Bowlen reported to work every day to oversee multimillion-dollar upgrades to the team’s training facilities and roster. So his absence from Dove Valley headquarters on Wednesday as players reported for physicals on the eve of training camp was as jarring as the announcement that the 70-year-old Bowlen was giving up control of the team because of Alzheimer’s disea...</div> <h5><a rel="item-license" href="#license-582177302014-07-24T17:41:25.24-06:00" id="#license-2014-07-24T17:41:25.24-06:00"> Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</a></h5> </div> 58217730@www.sltrib.com Thu, 24 Jul 2014 17:41:25 MDT Broncos owner giving up control due to Alzheimer’s http://www.sltrib.com/sltrib/sports/58215048-77/broncos-bowlen-team-pat.html.csp <div class="hnews hentry item"> <h4><a class="url entry-title" href="http://www.sltrib.com/sltrib/sports/58215048-77/broncos-bowlen-team-pat.html.csp">Broncos owner giving up control due to Alzheimer’s</a></h4> <span class="author source-org vcard"><span class="org fn">The Associated Press</span></span> <h5><span class="updated" title="2014-07-24T17:41:26.294-06:00">Updated Jul 24, 2014 05:41PM MDT</span></h5> <div class ="entry-content">Englewood, Colo. • Denver Broncos owner Pat Bowlen is giving up control of the team because of Alzheimer’s disease. The 70-year-old Bowlen will no longer be a part of the club’s daily operations, the Broncos announced Wednesday. Team President Joe Ellis is adding the title of chief executive officer and will have final say on all matters. The Broncos say the ownership of the franchise is held in a trust Bowlen set up more than a decade ago in hopes that one of his seven children will one day run...</div> <h5><a rel="item-license" href="#license-582150482014-07-24T17:41:26.294-06:00" id="#license-2014-07-24T17:41:26.294-06:00"> Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</a></h5> </div> 58215048@www.sltrib.com Thu, 24 Jul 2014 17:41:26 MDT New brain protein tied to Alzheimer’s disease http://www.sltrib.com/sltrib/world/58192086-68/brain-alzheimer-protein-tau.html.csp <div class="hnews hentry item"> <h4><a class="url entry-title" href="http://www.sltrib.com/sltrib/world/58192086-68/brain-alzheimer-protein-tau.html.csp">New brain protein tied to Alzheimer’s disease</a></h4> <h5><span class="updated" title="2014-07-16T19:56:03.118-06:00">Updated Jul 16, 2014 07:56PM MDT</span></h5> <div class ="entry-content">Scientists have linked a new protein to Alzheimer’s disease, different from the amyloid and tau that make up the sticky brain plaques and tangles long known to be its hallmarks. The discovery could give a new target for developing drugs and other treatments for Alzheimer’s, the most common form of dementia. It also might help explain why many people have plaques and tangles in their brain yet show no symptoms of the disease. Autopsies on 342 brains revealed that people who had the new protein w...</div> <h5><a rel="item-license" href="http://www.sltrib.com/pages/privacy"> Copyright 2013 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</a></h5> </div> 58192086@www.sltrib.com Wed, 16 Jul 2014 19:56:03 MDT Genentech Alzheimer’s drug misses goals in studies http://www.sltrib.com/sltrib/world/58190254-68/drug-alzheimer-genentech-studies.html.csp <div class="hnews hentry item"> <h4><a class="url entry-title" href="http://www.sltrib.com/sltrib/world/58190254-68/drug-alzheimer-genentech-studies.html.csp">Genentech Alzheimer’s drug misses goals in studies</a></h4> <span class="author vcard"><span class="fn">By MARILYNN MARCHIONE</span></span> <span class="source-org vcard"><span class="org fn"> The Associated Press</span></span> <h5><span class="updated" title="2014-07-16T09:59:10.966-06:00">Updated Jul 16, 2014 09:59AM MDT</span></h5> <div class ="entry-content">An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer’s disease, but showed some promise in the least-impaired participants who received a higher dose. Pneumonia and deaths were more common among those receiving the drug, but researchers downplayed that. Study leader Dr. Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rat...</div> <h5><a rel="item-license" href="#license-581902542014-07-16T09:59:10.966-06:00" id="#license-2014-07-16T09:59:10.966-06:00"> Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</a></h5> </div> 58190254@www.sltrib.com Wed, 16 Jul 2014 09:59:10 MDT Genentech Alzheimer’s drug misses goals in studies http://www.sltrib.com/sltrib/money/58190049-79/drug-alzheimer-genentech-studies.html.csp <div class="hnews hentry item"> <h4><a class="url entry-title" href="http://www.sltrib.com/sltrib/money/58190049-79/drug-alzheimer-genentech-studies.html.csp">Genentech Alzheimer’s drug misses goals in studies</a></h4> <span class="author vcard"><span class="fn">By MARILYNN MARCHIONE</span></span> <span class="source-org vcard"><span class="org fn"> The Associated Press</span></span> <h5><span class="updated" title="2014-07-16T17:26:12.193-06:00">Updated Jul 16, 2014 05:26PM MDT</span></h5> <div class ="entry-content">An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer’s disease, but showed some promise in the least-impaired participants who received a higher dose. Pneumonia and deaths were more common among those receiving the drug, but researchers downplayed that. Study leader Dr. Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rat...</div> <h5><a rel="item-license" href="#license-581900492014-07-16T17:26:12.193-06:00" id="#license-2014-07-16T17:26:12.193-06:00"> Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</a></h5> </div> 58190049@www.sltrib.com Wed, 16 Jul 2014 17:26:12 MDT